Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.

Antiviral research - 1 Oct 2025

Ichikawa Takaya, Tamura Tomokazu, Nao Naganori, Suzuki Hikoyu, Maruyama Shuhei, Wada Daiki, Tsujino Shuhei, Yoshinaga Noriyoshi, Asagoe Kohsuke, Takahata Mutsumi, Ishio Takashi, Ibata Makoto, Yoko Tanino, Kakinoki Yasutaka, Okubo Kazuhiro, Suzuki Rigel, Suzuki Saori, Nakamori Yasushi, Teshima Takanori, Fukuhara Takasuke

Abstract excerpt

Immunocompromised patients (ICPs), such as those who receive certain immunosuppressive therapies, occasionally experience prolonged viral infections even after antiviral treatment. In some cases, antiviral-resistant viruses may eventually emerge. Remdesivir (RDV) is an adenosine nucleoside analog that inhibits the activity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA polymerase, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate
Share to Alanine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to Immunocompromised Host

Share to SARS-CoV-2

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 40885288
DOI: 10.1016/j.antiviral.2025.106264

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.PMID 40885288Read ↗

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)Semantic proximity Read ↗

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug ResistanceSemantic proximity Read ↗

Remdesivir resistance in transplant recipients with persistent COVID-19Semantic proximity Read ↗

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivirSemantic proximity Read ↗

Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant RecipientSemantic proximity Read ↗

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.Semantic proximity Read ↗

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms.Semantic proximity Read ↗

Remdesivir Treatment alters Circulating MicroRNA Profile in Coronavirus Disease 2019 (COVID-19) PatientsSemantic proximity Read ↗

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.Semantic proximity Read ↗

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infectionsSemantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.